AL01211

AL01211 is a potent, oral, non-brain-penetrant small molecule inhibitor of glucosylceramide synthase (GCS), developed by AceLink Therapeutics for the treatment of Fabry disease and Type 1 Gaucher disease. As a substrate reduction therapy (SRT), AL01211 works by inhibiting GCS, the enzyme responsible for the first step in glycosphingolipid synthesis. This inhibition reduces the production and accumulation of toxic glycosphingolipids such as globotriaosylceramide (Gb3) in tissues like the heart and kidneys—organs commonly affected in Fabry disease—while minimizing central nervous system exposure to avoid related side effects. AL01211 is designed for once-daily oral administration and has demonstrated high potency, excellent selectivity, favorable pharmacokinetics, and safety in Phase 1 trials with healthy volunteers. It offers an alternative to intravenous enzyme replacement therapies currently used for these lysosomal storage disorders[1][2][3][5][6][7][8].